Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
NCT ID NCT07676877
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This trial tests whether adding low-dose total body irradiation (TBI) to standard chemotherapy before CAR T-cell therapy (tisagenlecleucel) is safe and effective for adults with large B-cell lymphoma that has returned or not responded to prior treatments. The study involves 18 participants and aims to find the best dose of TBI that can be given safely. If it works, this approach could help more patients achieve remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
low-dose total body irradiation plus tisagenlecleucel (CAR T-cell therapy)
What this could lead to
If successful, this combination could improve the effectiveness of CAR T-cell therapy for patients with hard-to-treat large B-cell lymphoma.
What could go wrong
This is an early-phase trial with only 18 participants, so results may not apply broadly. Adding radiation may increase side effects like low blood counts or organ toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact